Highest-materiality recent filing
bioAffinity Q2 revenue up 19% to $1.5M; CyPath Lung volume +216% YoY
Q2 2026 revenue $1.5M, up 19% YoY; net loss narrowed to $3.4M from $4.1M.
bioAffinity receives Nasdaq delisting notice for bid price non-compliance; plans appeal
Received Staff Determination on July 30, 2026, for bid price below $1.00 for 30 consecutive business days.
bioAffinity Technologies reports Q2 2026 CyPath Lung sales up >200% YoY, record quarter
Q2 2026 CyPath Lung sales volume >200% YoY and >30% over Q1 2026.
CyPath Lung unit sales in April 2026 increased nearly 300% vs. April 2025; ordering physician sites up 69% Q1 2025 to Q1 2026.
bioAffinity Technologies closes $3.2M public offering of common stock and pre-funded warrants
Offering of 1,040,000 shares at $0.80 each and pre-funded warrants for 2,960,000 shares at $0.793 each.
bioAffinity CyPath Lung unit sales nearly 300% higher in April 2026 vs 2025
Record monthly CyPath Lung unit sales in April 2026; preliminary data shows ~300% YoY increase over April 2025.
bioAffinity Q1 2026: CyPath Lung sales +146% YoY, revenue $1.4M, net loss $3.6M
CyPath Lung unit sales rose 146% YoY; testing revenue up 114% to $361,000.
BioAffinity stockholders approve reverse stock split, 2024 plan share increase to 1M
Stockholders approved reverse stock split at ratio of 1-for-2 to 1-for-250, at board's discretion.
bioAffinity Q1 2026 CyPath Lung unit sales surge 146% YoY, beat projections
Q1 2026 CyPath Lung unit sales up 146% YoY, exceeding internal projections on accelerating physician adoption.
bioAffinity 2025 revenue $6.2M; CyPath Lung revenue up 87% YoY, net loss $14.9M
Total revenue $6.2M, down 34% from $9.4M in 2024 due to discontinuing unprofitable pathology services.
bioAffinity initiates 2K-patient longitudinal study for CyPath Lung diagnostic
2,000-patient longitudinal study to evaluate CyPath Lung for early lung cancer detection in high-risk patients with nodules 6-29mm.
bioAffinity Technologies maintains CAP accreditation for lab subsidiary PPLS
Precision Pathology Laboratory Services (PPLS) passed rigorous CAP on-site inspection, retaining gold-standard accreditation.
bioAffinity Q3 2025: revenue down to $1.5M, CyPath Lung revenue up 122% YoY, net loss $5.1M
Total revenue $1.5M in Q3 2025, down 38% from $2.4M in Q3 2024 due to discontinuation of unprofitable pathology services.
bioAffinity reports CyPath Lung test volume up 111% in Oct vs 2025 monthly avg
October test volume increased 111% over 2025 monthly average; Q3 volume rose 95% sequentially.
bioAffinity regains Nasdaq compliance; stock continues trading on Capital Market
Received Nasdaq letter Oct 14 confirming compliance with minimum bid price ($1.00) and stockholders' equity ($2.5M) rules.
bioAffinity closes $4.8M public offering; Nasdaq compliance extension received
Gross proceeds of $4.8M from sale of 1,921,761 shares/pre-funded warrants at $2.50/$2.493 per unit.
bioAffinity Technologies announces 1-for-30 reverse stock split effective Sept 19, 2025
1-for-30 reverse stock split effective at open of trading on Nasdaq on September 19, 2025.
Increased floor price in May 2025 and August 2025 warrants from $0.10 to $0.15, effective August 12, 2025.
bioAffinity closes $1.45M capital raise and reclassifies warrants adding $2.8M to equity
Private placement of 990 Series B Preferred shares convertible into ~4.3M common at $0.23/sh and warrants for ~6.7M shares at $0.352/sh, gross proceeds ~$1.2M.
On April 12, 2025, Stuart Diamond, a member of the board of directors (the “Board”) of bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), notified the Company of his decision not to stand for re-election at the Company’s 2025 annual meeting of stockholders (the “2025 Annual Meeting”).
On October 4, 2024, the Board of Directors (the “Board”) of bioAffinity technologies, Inc. (the “Company”) appointed J. Michael Edwards, who has served as the Company’s Interim Chief Financial Officer, as a consultant, since September 2024, to serve as Chief Financial Officer of the Company, effective November 5, 2024.
Michael Dougherty notified bioAffinity Technologies, Inc. (the "Company") of his decision to resign from his position as the Company’s Chief Financial Officer and Principal Accounting Officer to pursue other opportunities.
the Board of Directors of the Company appointed, effective as of September 16, 2024, Michael Edwards, age 57, to serve as the Company’s Interim Chief Financial Officer and Principal Accounting Officer.
On December 1, 2023 , Mohsin Y. Meghji resigned from the Board of Directors, effective immediately, for personal reasons, and not due to any disagreement with the Company or its operations, policies or practices.
On December 1, 2023, the Board of Directors (the “Board”) of bioAffinity Technologies, Inc. (the “Company”) appointed Jamie Platt, Ph.D., to serve as a director of the Company.
Xavier Reveles, age 54, who has served as the Company’s Vice President of Operations as an employee at will since September 2022, was appointed to serve as the Company’s Chief Operating Officer on September 18, 2023, contingent upon and effective as of the consummation of the Acquisition.
Roby P. Joyce, MD, age 75, was appointed to serve on the Company’s Board of Directors on September 18, 2023, contingent upon and effective as of the consummation of the Acquisition.
Effective May 1, 2023, the Company appointed Michael Dougherty (age 44) to serve as the Company’s new Vice President and Chief Financial Officer (principal financial officer and principal accounting officer).
Effective May 1, 2023, Michael Edwards, the Company’s Chief Financial Officer (principal financial officer and principal accounting officer), resigned.
Max materiality 0.85 · Median 0.50 · Most common event other_material